Skip to content
Hemispherx Biopharma, Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

Press Releases

 
Oct 14, 2003
HEMISPHERX BIOPHARMA EXPANDS SARS PREVENTION/TREATMENT INITIATIVE

Sep 15, 2003
HEMISPHERX BIOPHARMA REPORTS ON ANNUAL MEETING

Sep 15, 2003
HEMISPHERX BIOPHARMA REPORTS ON ANNUAL MEETING

Sep 04, 2003
HEMISPHERX BIOPHARMA SIGNS AGREEMENT WITH GUANGDONG MEDICINE GROUP CORPORATION

Aug 20, 2003
HEMISPHERX BIOPHARMA SECOND QUARTER EARNINGS ANNOUNCED

Aug 18, 2003
HEMISPHERX BIOPHARMA ENTERS INTO SALES AND MARKETING AGREEMENT WITH ENGITECH FOR ALFERON N

Aug 11, 2003
HEMISPHERX BIOPHARMA ENTERS INTO AGREEMENT WITH THE JOHANN WOLFGANG GOETHE UNIVERSITY, INSTITUTE OF VIROLOGY

Aug 04, 2003
HEMISPHERX BIOPHARMA RECEIVES NEW PATENTS FOR ORAL DOSED BROAD-SPECTRUM IMMUNE ACTIVATORS

Jul 29, 2003
HEMISPHERX REPORTS AMPLIGEN PREVENTS DESTRUCTION OF NERVE CELLS AND INCREASES SURVIVAL RATES IN FLAVIVIRUS INFECTION

Jul 15, 2003
HEMISPHERX REPORTS NEW HIV TREATMENT DATA ON AMPLIGEN AT THE 2nd IAS CONFERENCE ON HIV PATHOGENESIS AND TREATMENT

 60   61   62   63   64     65    66   67   68   69   70 
 <<   <   >   >> 
Hemispherx Biopharma, Inc. Logo White

Latest News

  • CEO Roadshow Interviews Hemispherx Thomas K. Equels
  • Introducing You to the First Ampligen Quarterly Update
  • Proactive Investors USA Sits Down with Hemispherx CEO Thomas K. Equels

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright | All Rights Reserved | AIM ImmunoTech Inc. | Privacy Policy | Terms of Use
FacebookTwitterYouTubeLinkedIn

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window